Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy

Alexander A. Parikh, Bernhard Gentner, Tsung Teh Wu, Steven A. Curley, Lee M. Ellis, Jean Nicolas Vauthey

Research output: Contribution to journalArticle

Abstract

Systemic chemotherapy is used increasingly prior to resection of hepatic colorectal metastases. Previous reports have indicated an increased risk of perioperative complications associated with the use of systemic chemotherapy prior to resection. The purpose of this study was to investigate perioperative complications in patients receiving neoadjuvant systemic chemotherapy consisting of 5-fluorouracil (5-FU) and leucovorin (LV) with or without CPT-11 within 6 months of major liver resection. A retrospective review of 108 patients undergoing major liver resection for colorectal metastases with curative intent from 1997 to 2002 was performed. Patient and tumor characteristics, perioperative parameters, and morbidity and mortality were measured. Forty-seven patients (44%) received no chemotherapy, 27 patients (25%) received systemic 5-FU/LV, and 34 (31%) received systemic 5-FU/LV/CPT-11. A significantly higher number of patients in the group treated with preoperative 5-FU/LV plus CPT-11 had multiple tumors. Patients in this group also tended to have smaller tumors, fewer complications, and a higher R0 margin resection rate, but these findings were not statistically significant. Median blood loss and length of hospital stay were also not significantly different. There were no perioperative deaths. We conclude that the use of fluoropyrimidine-based chemotherapy and CPT-11 prior to major liver resection is not associated with increased morbidity or mortality. It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases.

Original languageEnglish
Pages (from-to)1082-1088
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume7
Issue number8
DOIs
Publication statusPublished - Dec 1 2003

Fingerprint

irinotecan
Drug Therapy
Leucovorin
Liver
Fluorouracil
Neoplasm Metastasis
Length of Stay
Morbidity
Neoplasms
Mortality

Keywords

  • Complications
  • Liver resection
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Surgery

Cite this

Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. / Parikh, Alexander A.; Gentner, Bernhard; Wu, Tsung Teh; Curley, Steven A.; Ellis, Lee M.; Vauthey, Jean Nicolas.

In: Journal of Gastrointestinal Surgery, Vol. 7, No. 8, 01.12.2003, p. 1082-1088.

Research output: Contribution to journalArticle

Parikh, Alexander A. ; Gentner, Bernhard ; Wu, Tsung Teh ; Curley, Steven A. ; Ellis, Lee M. ; Vauthey, Jean Nicolas. / Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. In: Journal of Gastrointestinal Surgery. 2003 ; Vol. 7, No. 8. pp. 1082-1088.
@article{ba00f58e064140d5a3c9e757e2591008,
title = "Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy",
abstract = "Systemic chemotherapy is used increasingly prior to resection of hepatic colorectal metastases. Previous reports have indicated an increased risk of perioperative complications associated with the use of systemic chemotherapy prior to resection. The purpose of this study was to investigate perioperative complications in patients receiving neoadjuvant systemic chemotherapy consisting of 5-fluorouracil (5-FU) and leucovorin (LV) with or without CPT-11 within 6 months of major liver resection. A retrospective review of 108 patients undergoing major liver resection for colorectal metastases with curative intent from 1997 to 2002 was performed. Patient and tumor characteristics, perioperative parameters, and morbidity and mortality were measured. Forty-seven patients (44{\%}) received no chemotherapy, 27 patients (25{\%}) received systemic 5-FU/LV, and 34 (31{\%}) received systemic 5-FU/LV/CPT-11. A significantly higher number of patients in the group treated with preoperative 5-FU/LV plus CPT-11 had multiple tumors. Patients in this group also tended to have smaller tumors, fewer complications, and a higher R0 margin resection rate, but these findings were not statistically significant. Median blood loss and length of hospital stay were also not significantly different. There were no perioperative deaths. We conclude that the use of fluoropyrimidine-based chemotherapy and CPT-11 prior to major liver resection is not associated with increased morbidity or mortality. It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases.",
keywords = "Complications, Liver resection, Preoperative chemotherapy",
author = "Parikh, {Alexander A.} and Bernhard Gentner and Wu, {Tsung Teh} and Curley, {Steven A.} and Ellis, {Lee M.} and Vauthey, {Jean Nicolas}",
year = "2003",
month = "12",
day = "1",
doi = "10.1016/j.gassur.2003.08.005",
language = "English",
volume = "7",
pages = "1082--1088",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York LLC",
number = "8",

}

TY - JOUR

T1 - Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy

AU - Parikh, Alexander A.

AU - Gentner, Bernhard

AU - Wu, Tsung Teh

AU - Curley, Steven A.

AU - Ellis, Lee M.

AU - Vauthey, Jean Nicolas

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Systemic chemotherapy is used increasingly prior to resection of hepatic colorectal metastases. Previous reports have indicated an increased risk of perioperative complications associated with the use of systemic chemotherapy prior to resection. The purpose of this study was to investigate perioperative complications in patients receiving neoadjuvant systemic chemotherapy consisting of 5-fluorouracil (5-FU) and leucovorin (LV) with or without CPT-11 within 6 months of major liver resection. A retrospective review of 108 patients undergoing major liver resection for colorectal metastases with curative intent from 1997 to 2002 was performed. Patient and tumor characteristics, perioperative parameters, and morbidity and mortality were measured. Forty-seven patients (44%) received no chemotherapy, 27 patients (25%) received systemic 5-FU/LV, and 34 (31%) received systemic 5-FU/LV/CPT-11. A significantly higher number of patients in the group treated with preoperative 5-FU/LV plus CPT-11 had multiple tumors. Patients in this group also tended to have smaller tumors, fewer complications, and a higher R0 margin resection rate, but these findings were not statistically significant. Median blood loss and length of hospital stay were also not significantly different. There were no perioperative deaths. We conclude that the use of fluoropyrimidine-based chemotherapy and CPT-11 prior to major liver resection is not associated with increased morbidity or mortality. It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases.

AB - Systemic chemotherapy is used increasingly prior to resection of hepatic colorectal metastases. Previous reports have indicated an increased risk of perioperative complications associated with the use of systemic chemotherapy prior to resection. The purpose of this study was to investigate perioperative complications in patients receiving neoadjuvant systemic chemotherapy consisting of 5-fluorouracil (5-FU) and leucovorin (LV) with or without CPT-11 within 6 months of major liver resection. A retrospective review of 108 patients undergoing major liver resection for colorectal metastases with curative intent from 1997 to 2002 was performed. Patient and tumor characteristics, perioperative parameters, and morbidity and mortality were measured. Forty-seven patients (44%) received no chemotherapy, 27 patients (25%) received systemic 5-FU/LV, and 34 (31%) received systemic 5-FU/LV/CPT-11. A significantly higher number of patients in the group treated with preoperative 5-FU/LV plus CPT-11 had multiple tumors. Patients in this group also tended to have smaller tumors, fewer complications, and a higher R0 margin resection rate, but these findings were not statistically significant. Median blood loss and length of hospital stay were also not significantly different. There were no perioperative deaths. We conclude that the use of fluoropyrimidine-based chemotherapy and CPT-11 prior to major liver resection is not associated with increased morbidity or mortality. It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases.

KW - Complications

KW - Liver resection

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0347481231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347481231&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2003.08.005

DO - 10.1016/j.gassur.2003.08.005

M3 - Article

C2 - 14675719

AN - SCOPUS:0347481231

VL - 7

SP - 1082

EP - 1088

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 8

ER -